Nucleic Acid, Nucleoside, or Nucleotide – Page 7

Gilead and Merck’s Investigational HIV Combo Shows Promising Long-Term Viral Suppression in Phase 2 Trial

8 months ago talkbio0Tagged Co., HIV, islatravir, Lenacapavir, Merck & Co., oral regimen, Phase 2 clinical trial, viral suppression, Weekly

HIV treatment, Weekly oral regimen, Islatravir, Lenacapavir, Viral suppression, Phase 2 clinical trial, Gilead Sciences, Merck & Co.

Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies

8 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biotechnology, Drug Discovery, Eli, Eli Lilly, GalNAc, Insitro, Metabolic Diseases, pharmaceutical partnership, RNA, Small Interfering

Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership

Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

8 months ago talkbio0Tagged Agreement, Antibody Therapy, Aortic Valve Insufficiency, Artificial Intelligence, Drug Development, Eli, Eli Lilly, Insitro, MASLD, Metabolic, Metabolic Diseases, RNA, Small Interfering, steatotic liver disease, strategic

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup

8 months ago talkbio0Tagged Alnylam, Cities, Genetic Engineering, RNA Interference, RNA, Small Interfering

RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup

Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation

8 months ago talkbio0Tagged Chemoradiotherapy, Johnson and Johnson, Malignant neoplasm of urinary bladder, SunRISe-1, TAR 200

Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study

Judo Bio Launches with $100M to Pioneer Kidney-Targeted siRNA Therapies

8 months ago talkbio0Tagged genetic medicines, Judo Bio, Kidney Diseases, megalin-STRIKERS, oligonucleotide medicines, RNA, Small Interfering, Strikes, Employee

Judo Bio, siRNA therapies, kidney diseases, oligonucleotide medicines, STRIKE platform, megalin-STRIKERS, renal diseases, genetic medicines.

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

8 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development